Medication selection in depression still relies primarily on trial and error, frustrating both patients and clinicians. Diagnostic tests that predict treatment response in advance could facilitate an informed approach and reduce suffering. Ideally, those tests would directly measure brain function. The primary research test of brain function, functional magnetic resonance imaging (fMRI), is too expensive to scale to routine care. Electroencephalography (EEG), however, is comparatively inexpensive and fast and could be made available in many settings. Plus, as a direct measure of localized brain activity, EEG is ideal for dissecting the connections between neurotransmission, symptoms, and pharmacologic response.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Grzenda A, Widge AS. Electroencephalographic Biomarkers for Predicting Antidepressant Response: New Methods, Old Questions. JAMA Psychiatry. 2020;77(4):347–348. doi:10.1001/jamapsychiatry.2019.3749
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: